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The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool
for the treatment of type 2 diabetes mellitus. The actions of GLP-1 on -cells and the nervous and
digestive systems arewell known. The action of this peptide in adipose tissue (AT), however, is still
poorly defined. Furthermore, no relationship has been established between GLP-1 receptor (GLP-
1R) in AT and obesity and insulin resistance (IR). We provide evidence for the presence of this
receptor in AT and show that its mRNA and protein expressions are increased in visceral adipose
depots frommorbidly obesepatientswith ahighdegreeof IR. Experimentswith the3T3-L1 cell line
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showed the lipolytic and lipogenic dose-dependent effect of GLP-1. Moreover, GLP-1 stimulated
lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate
cyclase/cAMP signaling. Our data also demonstrate that the expression of the GLP-1R in AT cor-
related positively with the homeostasis model assessment index in obese IR subjects. Furthermore,
prospective studies carried out with patients that underwent biliopancreatic diversion surgery
showed that subjectswith high levels of GLP-1R expression in AT,which indicates a deficit of GLP-1
in this tissue,were thosewhose insulin sensitivity improved after surgery, suggesting the potential
relationship between AT GLP-1R and insulin sensitivity amelioration in obese subjects. Altogether
these results indicate that the GLP-1/GLP-1R system in AT represents another potential candidate
for improving insulin sensitivity in obese patients. (Endocrinology 152: 0000–0000, 2011)
The prevalence of obesity is increasing and has reachedepidemicproportions.Obesity is frequently associated
with the inability of tissue to handle insulin, with a clear
tendency to develop an insulin-resistant environmental
factor. The accepted events in the context of insulin resis-
tance (IR) include increased insulin production, leading to
hyperinsulinemia, and the compensatory failure of insulin
secretion by the -cells, which leads to the emergence of
type 2 diabetes mellitus (DM2) (1). In this scenario, vis-
ceral fat plays a determinant role linking central obesity
with the onset of IR (2–4). Furthermore, other data sug-
gest the link between adipose cell size, increased insulin
resistance, and diabetes (5).
Epidemiological studies have established a strong
correlation between obesity and diabetes, with popu-
lation-based studies showing a linear increase in the rate
of diabetes for every kilogram gained (6).
However, multiple consistent lines of evidence indicate
that no clear cutoff for developing IR can be defined for a
specific degree of obesity due to the paradox that some
morbidly obese subjects do not develop diabetes, whereas
some lean subjects do. Thus, several studies have focused
on the analysis of adipose tissue dysfunction as one of the
driving factors in the development of insulin resistance
and finally DM2.
Glucagon-like peptide 1 (GLP-1) amide (7–36) is an
enteroendocrine-derived peptide secreted in response to
nutrient ingestion. GLP-1 stimulates insulin biosynthesis
and secretion in a glucose-dependent manner, thus in-
creasing the sensitivity to glucose (7, 8). In addition,
GLP-1 improves -cell glucose sensing in patients with
DM2 (9). GLP-1 also inhibits gastric emptying and con-
trols food intake by increasing satiety in treated DM2 pa-
tients (10, 11).
The effect of GLP-1 in adipose tissue (AT) has been
poorly studied, and only a few reports exist on this issue.
Studies performed in isolated rat and human adipocytes
(12–15) have demonstrated that GLP-1 has the ability to
induce both lipogenic and lipolytic mechanisms, with in
vivo studies showing inhibition of fasting lipolysis (16).
These GLP-1 effects in fat, like those in liver and muscle,
are exerted through a GLP-1-specific receptor and struc-
turally or functionally distinct from that expressed in the
pancreas (17). Furthermore, the presence of GLP-1 recep-
tor (GLP-1R) and its function have been widely studied in
3T3-L1 adipocytes (18),whereas themolecular identity of
GLP-1R in human AT remains unclear.
The main objective of this work was to verify the pres-
ence ofGLP-1R in humanATand correlate the expression
levels of this receptor with the degree of insulin resistance.
Materials and Methods
Subjects and processing of biological samples
This section is detailed in SupplementalData1, publishedonThe
Endocrine Society’s Journals Online web site at http://endo.
endojournals.org. Anthropometric measurements are shown in
Supplemental Data 2. Analytical methods are shown in Supple-
mental Data 2.
Western blotting analysis
Proteins were extracted from samples [sc AT (SAT) and vis-
ceral AT (VAT)], pulverized in liquid nitrogen, homogenized,
and lysed in 1:20 (wt/vol) of T-PERreagent andprotease inhibitor
cocktail, sonicated, and centrifuged. The protein concentration of
each supernatant was quantified using a Coomassie protein assay
kit. About 20 g of protein was separated into 15% sodium
dodecyl sulfate-polyacrylamide gel and transferred to polyvinyl
difluoride membranes. These membranes were incubated over-
night at 4 C with antibodies to GLP-1R (Abcam, Cambridge,
MA) or monoclonal anti--actin, followed by incubation with
horseradish peroxidase-conjugated secondary antibody. The
proteins were visualized with SuperSignal West Pico chemilu-
minescent substrate (ThermoFisher Scientific) and quantified by
Auto-Chemi system and Labworks 4.6 image acquisition anal-
ysis software (UVP, Inc., CA). Data were normalized to the cor-
responding -actin band intensities.
Immunohistochemistry of AT
Five-micron sections of formalin-fixed, paraffin-embedded
human AT were deparaffinized and rehydrated before antigen
unmaskingwith pepsin at 37C. Sectionswere blocked in normal
serum and incubated overnight with mouse antihuman GLP-1R
at 1:100 dilutions. Secondary antibody staining was performed
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using the VECTASTAIN ABC kit (Vector Laboratories, Burl-
ington, Ontario, Canada) and detected with diaminobenzidine.
Sections were counterstained with hematoxylin before dehydra-
tion and coverslip placement. As a negative control, the entire
immunohistochemical procedure was performed on adjacent
sections in the absence of primary antibodies (Abcam,
Cambridge).
3T3-L1 cell culture and in vitro experimental
setups
In vitro experiments were performed on 3T3-L1 cells differ-
entiated by adipocytes, as previously described (17). Briefly, cells
were grown inDMEM(CambrexBio Science,Vervies, Belgium),
supplemented with 10% fetal bovine serum (Sera-Lab Ltd.,
Crawley Down, UK), 4 mM glutamine, and 1,5 g/liter H2CO3
(culture medium) at 37 C and 5% CO2 until 100% confluence
was reached (d 0). Subsequently, cells were incubated inDMEM
containing 0.5 mM isobutylmethylxanthine (IBMX), 0.25 M
dexamethasone, and 10 g/ml insulin for 72 h (d 3). Thereafter
themediumwas replacedbyDMEMcontaining10g/ml insulin
for an additional 72 hperiod (d 6) and then exchanged by culture
medium until d 10, when all the experiments were carried out.
On the day of the experiments, differentiated 3T3-L1 adipocytes
were preincubated in 1 ml serum-free culture medium (DMEM,
1 g/liter glucose) for 2 h. Medium was then replaced by DMEM
alone or containing 10 nM or 100 nM GLP-1 (fragment 7–36,
Sigma G8147; Sigma-Aldrich, London, UK). After a 12-h treat-
ment period, cells were harvested for RNA analysis and protein
quantification, and supernatants were used to determine lipol-
ysis. In another set of experiments, we explored the contribution
of the adenylate cyclase/cAMP pathway to GLP-1 lipolytic re-
sponse by incubating cells for 4 h with 100 nM GLP-1 in the
presence or absence of the specific blocker of the enzyme, [cis-
N-(2-phenylcyclopentyl) azacyclotridec-1-en-2-amine HCl]
(MDL-12,330A; 106 M). This inhibitor was added alone to cell
cultures 90 min before the 4-h combined treatment. Medium
samples were collected at the end of each experiment.
Measurement of cAMP production
To elucidate the effect of GLP-1 on intracellular cAMP pro-
duction, differentiated3T3-L1 cellswere incubated for 60min in
the absence or presence ofGLP-1 (100nM) or theGLP-1 receptor
antagonist exendin (9–39) (10 nM) alone or in combination. The
effects of glucagon (10 nM) and glucose-dependent insulino-
tropic polypeptide (GIP)-1 (10 nM) on intracellular cAMP accu-
mulation in 3T3-L1 cell cultures were also assessed. At the end
of the experiments, mediawere removed, lysis buffer was added,
and lysates were removed and stored at 20 C for analysis of
intracellular cAMP accumulation by enzyme immunoassay ac-
cording to the manufacturer’s instructions (cAMP Direct Bio-
track enzyme immunoassay; GE Healthcare, Barcelona, Spain).
Unless otherwise indicated, all other reagentswere purchased
from Sigma Aldrich.
Human preadipocyte isolation and primary culture
Abdominal white adipose tissue samples were washed twice
with PBS and minced removing the blood vessels. Samples were
then digested in a water bath with collagenase I (1 g/ml) at 37
C for 30 min followed by several washes in PBS, filtrations, and
centrifugations (800 rpm) with 250 and 100 m nylon mashes.
Erythrocytes were removed with red blood cell lysis buffer (155
mM NH4Cl, 10 mM KHCO3, 2 mM NaEDTA), and cells were
centrifuged for 5 min at 800 rpm. Preadipocytes were then re-
suspended in human omental preadipocyte medium [DMEM/
Hams F-12 medium (1:1, vol/vol); HEPES pH 7.4; fetal bovine
serum; penicillin; streptomycin; amphotericin B] and plated in
12- and 96-well plates. Media were changed every 2–3 d until
cells reached confluence. For the differentiation protocol, cells
were culturedwithOM-DM[DMEM/HamsF-12medium (1:1,
vol/vol); HEPES pH 7.4; fetal bovine serum; biotin; panto-
thenate; human insulin; dexamethasone; IBMX; peroxisomal
proliferator-activated receptor- agonist; penicillin; strepto-
mycin; amphotericin B] for 1wk changing themedia every 2–3
d, followed by another week in human omental adipocyte me-
dium [DMEM/Hams F-12 medium (1:1, v/v); HEPES, pH 7.4;
fetal bovine serum; biotin; pantothenate; human insulin; dexa-
methasone; penicillin; streptomycin; amphotericin B]. Mature
adipocytes were then treated with different concentrations of
GLP-1 (10 nM, 100 nM, and 1 M) for 12 h before cells were
harvested for RNA isolation.
Lipolysis assays
After these experimental treatments, media from3T3-L1 and
humanprimary cell cultureswere collected and the sampleswere
analyzed for free glycerol content using free glycerol reagent
(Sigma-Aldrich) following themanufacturer’s indications. Glyc-
erol content was normalized to protein concentrations in each
sample.
Total RNA isolation and real-time PCR
Total RNAwas extracted from3T3-L1, humanpreadipocyte
cell cultures, and human AT samples using TRIZOL reagent.
Total RNA samples were diluted to concentrations between 100
and 200 ng/l. An aliquot of the diluted total RNA samples was
used to determine RNA concentration and purity on the Nano-
Drop ND-1000 spectral photometer (Peqlab, Wilmington, DE).
Subsequently, mRNA amplifications were carried out using a
MicroAmp optical 96-well reaction plate (PE Applied Biosys-
FIG. 1. GLP-1R mRNA expression in SAT and VAT. GLP-1R mRNA
expression analysis was performed in human SAT and VAT from lean,
overweight, obese, and morbidly obese subjects with low (OB/L-IR) and
high (OB/H-IR) degrees of insulin resistance. mRNA were normalized to
cyclophilin levels. Results were obtained in triplicate and expressed as
the mean  SD (n  18 for lean, n  36 for overweight, n  19 for
obese, and n  22 for morbidly obese subjects). Bars with different
letters have a significant difference (P  0.05).
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tems, Foster City, CA) on an ABI 7500 real-time PCR system.
The amplifications were performed with MicroAmp optical 96-
well reaction plate (PE Applied Biosystems) on an ABI 7500
real-time PCR system (Applied Biosystems). Quantitative RT-
PCR reactions were carried out for all genes using specific Taq-
Man gene expression assays. A negative PCR control without
template and a positive PCR control with a template of known
amplification were included in each assay. During PCR the Ct
values (the cycle number at which the detected fluorescence ex-
ceeds the threshold) for each amplified product were determined
using a threshold value of 0.1. The specific signals were normal-
ized by constitutively expressed cyclophilin and 18s rRNA (as
indicated in each figure) signals using the formula 2-Ct for
mRNA expression in tissue fractions extracted from human AT
and 2-Ct for cell cultures incubated in the presence of GLP-1
taking the untreated control as a calibrator.
Statistical analyses
SSPS statistical software, version 11.0
for Windows (SSPS Inc., Chicago, IL) was
used for statistical analyses. The normal
distribution of variables to characterize
differences in gene expression or lipolytic
rates was assessed using the Kolmogorov-
Smirnov test, followed by the one-way
ANOVA test for the comparison of the dif-
ferent groups, and the statistical differences
were carried out by the use ofDuncan’s test.
Post hoc statistical analyseswere completed
by using the protected least-significant-dif-
ference test to identify significant differ-
ences between treatments in vitro. The Stu-
dent t test was used for the paired data of
morbidly obese subjects before and after
gastric bypass surgery. Differences were
considered significant at P 0.05. All data
presented in the text and figures are ex-
pressed as mean SD. The correlation anal-
ysis of mRNA quantitative expression for
eachof the geneswasperformedwithSpear-
man’s coefficient test (r).One-wayANOVA
followedbyaNewman-Keuls testwereused
for parametric data in cAMP study.
Results
Anthropometric and biochemical
characteristics of the study groups
Table 1 (Supplemental Data 3)
shows the main clinical and analytical
data of the study population grouped
by body mass index and functional IR
status. Body mass index and waist cir-
cumference increased progressively from
overweight to morbidly obese subjects.
Glucose levels were similar across the
groups. No differences in the homeosta-
sis model assessment (HOMA) index
were observed between the overweight, obese, andOB/L-IR
groups compared with the lean subjects, as intended in the
study design because we selected only those who had a low
degree of IR; however, HOMA index was significantly in-
creased in the OB/H-IR group compared with lean subjects.
These results were consistent with what we were expecting
because only nonmorbidly obese subjects with a low degree
of IR were included in the first three groups of the table
(Supplemental Data 3).
Adiponectin was significantly lower only in the OB/
H-IR group compared with the other groups. Neverthe-
less, no significant differences were detected between OB/
L-IR, obese, overweight, and lean subjects.
FIG. 2. GLP-1R protein expression in human AT. Western blot analysis of human AT yielded a
single 50-kDa band in both visceral (A) and subcutaneous (B) tissue corresponding to the
known molecular weight of human GLP-1R. Monoclonal anti--actin was applied as a loading
control. The blot is representative of three independent experiments with different samples
(n  6 lean, n  5 OB/L-IR, and n  6 OB/H-IR). *, Significance in the t test is indicated by
P  0.05; **, significance in the t test is indicated by P  0.01. C, Immunohistochemical
identification of GLP-1R in human VAT was performed using a specific antibody against this
protein. Control panel is representative of blue labeling corresponding to hematoxylin-labeled
nucleus. Positive cells showed brown labeling, especially at the mesothelium, endothelium,
and nucleus.
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GLP-1R gene and protein expression in AT
When we analyzed GLP-1R gene expression in both
adipose depots, we observed that there was a significant
progressive decrease in the VAT depot among the differ-
ent obesity groups (from lean to OB/L-IR morbidly obese
subjects). In contrast to the insulin-sensitive lean, over-
weight, and obese groups and the low insulin-resistant
group, the GLP-1R mRNA expression was increase by ap-
proximately 2.5-fold in the high insulin-resistant obese
group (Fig. 1). In SAT, no differences in GLP-1R gene ex-
pressionwereobservedbetween lean, overweight, andobese
subjects. However, a substantial increase in GLP-1R gene
expression was observed in both groups of morbidly obese
subjects compared with the lean group.
Regarding GLP-1R protein expression, we observed a
significantly reduced expression in VAT depots fromOB/
L-IR subjects when compared with the lean group. Con-
versely, forOB/H-IR subjects,GLP-1Rprotein expression
was found to be significantly higher compared with both
OB/L-IR and lean subjects (Fig. 2A). No differences were
observed in SAT depots (Fig. 2B).
To evaluate the weight of the different components of
theAT contributing toGLP-1R expression, immunostain-
ing using a specific GLP-1R antibodywas assayed. Both the
adipocyte and stromal-vascular fraction showed a positive
reaction, with a greater intensity in the latter (Fig. 2C).
GLP-1R gene expression in stromal-vascular and
adipocyte fraction from VAT and sc human
adipose tissue
Real-time PCR analysis of GLP-1R gene expression in
both stromal vascular and adipocyte fractions confirmed
the previous results obtained by immunostaining de-
scribed above. Thus, in a pool sample obtained from seven
lean and obese subjects, GLP-1R mRNA was expressed
both in adipocyte and stromal vascular fractions (Fig. 3A),
not at levelsusuallyobserved in stomach samples, inwhich
this receptor is known to be highly expressed but still sig-
nificantly high (Fig. 3B). A clear increase (almost 2.6-fold)
was observed in stromal vascular fraction compared with
isolated adipocytes mainly in VAT depots (Fig. 3A).
Effects of GLP-1 on lipolysis and cAMP production
To assess the effect of GLP-1 on adipocyte function, we
incubated differentiated adipocytes from the 3T3-L1
mouse cell line, in the absence or presence of 10 and 100
nMGLP-1. The addition of GLP-1 to culture cells induced
a significant enhancement of lipolysis measured by glyc-
erol release into the media (Fig. 4A). We subsequently
determined whether a major intracellular effector acti-
vated by GLP-1, adenylate cyclase, could be involved in
the lipolytic response of 3T3-L1 adipocytes to the peptide.
As shown in Fig. 4B, the specific adenylate cyclase inhib-
itorMDL-12,330A (106 M), which by itself did not mod-
ify basal lipolysis, suppressed the stimulation caused by
GLP-1 on the lipolytic activity of 3T3-L1 cells. On the
basis of these results, our next experiments attempted to
examine the effect of GLP-1 on cAMP production. Incu-
bation of 3T3-L1 cells with 100 nM GLP-1 increased
cAMP content almost 3-foldwith respect to that observed
in controls (Fig. 4C). The GLP-1-induced increase in
cAMP levels was blocked when the peptide was adminis-
tered in thepresenceof theGLP-1 specific receptorblocker
exendin (9–39) (Fig. 4C). The effects of glucagon andGIP,
bothofwhich are known to elevate cAMP levels,were also
assessed in 3T3-L1. This showed that cAMP levels in-
duced byGLP-1were slightly lower than those induced by
GIP and glucagon (Fig. 4C).
To further confirm the above results, we replicated the
study in human mature adipocytes differentiated from
AT-derived mesenchymal stem cells. GLP-1 treatment in
differentiated mature adipocytes induced a significant li-
polytic effect in a dose-dependent manner, reaching 50%
of the levels observed in thepresenceof thepositive control
obtained after incubating the cells with IBMX (Fig. 4D).
Prospective study in the morbidly obese cohort
This cohort was scheduled for bariatric surgery and
was reevaluated at the 6-month follow-up. In Table 2 of
the Supplemental Data 3, we represent the main anthro-
pometrical and metabolic variables of the morbidly obese
cohort, taken before surgery and 6 months later. As was
expected after massive weight loss, lipid and metabolic
parameters were notably improved in this cohort, with a
dramatic decrease in the HOMA index in the whole pop-
FIG. 3. GLP-1R mRNA expression in adipocyte and stromal-vascular
fractions from human adipose tissue. A, Adipocyte and stromal-
vascular fractions were isolated from SAT and VAT, and then GLP-1
receptor mRNA expression was analyzed in both. B, GLP-1R mRNA in
VAT adipocyte fraction was compared with that in stomach samples,
which represents a positive control of GLP-1R gene expression. Results
were obtained from triplicate experiments and expressed as the
mean  SD. *, P  0.05; **, P  0.001.
Endocrinology, November 2011, 152(11):0000–0000 endo.endojournals.org 5
ulation. Likewise, plasma adiponectin was increased with
an expected decrease in leptin circulating levels at the end
of the follow-up (Table 2 of the Supplemental Data 3).
Regarding GLP-1R adipose tissue expression, we ob-
served a strong positive correlation betweenGLP-1R gene
expression in VAT depots with the HOMA index and
waist circumference (r  0.485, P  0.19 and r 0.351,
P  0.002, respectively) (Fig. 5, A and B).
Interestingly, when we sought variables determining
improvement in the HOMA index after bariatric surgery,
we found that GLP-1R expression lev-
els in VAT depots correlated positively
with the decrease in the HOMA index
(Fig. 5, C and D).
Discussion
In the present work, we have shown for
the first time that GLP-1R in adipose
tissue is potentially associated with the
degree of insulin resistance. Thus, we
observed that subjects with morbid
obesity and a high degree of IR display
a clear increase in GLP-1R gene and
protein expression in visceral adipose
tissue. In addition,GLP-1RmRNAex-
pression in VAT depots was elicited as
an important determinant of the
HOMA index before and after surgical
weight loss in morbidly obese patients.
Until now, few studies have ad-
dressed GLP-1R in human AT; in fact,
when listing the tissues wherein GLP-1
exerts its action, AT is usually over-
looked (7, 8, 10, 11). Hence, there are
no published data relating to human
adipose tissue GLP-1R expression de-
pendent on the degree of insulin resis-
tance. The presence of theGLP-1 recep-
tor in isolated human and mouse
adipocytes has been reported since the
1990s (18–20). In the presentwork,we
further extended these findings bydem-
onstrating the expression of GLP-1R,
both at themRNAandprotein levels, in
the two main components of AT, ma-
ture adipocytes and stromal-vascular
cells, with a clear predominance in the
latter. Furthermore, immunohistochem-
ical analysis enabledus tounveil thepres-
enceofGLP-1Rin themesothelium,stro-
mal-vascular fraction, and adipocytes.
The picture displayed by GLP1-R expression in the
study cohort showed a different behavior, depending on
the adipose tissue depot analyzed. In SAT, no differences
in GLP-1R expression were noted in obese subjects with
low degrees of IR. In extremely obese patients classified as
morbidly obese (OB), a different pattern was observed in
our study. In these patients, in SAT depots, we observed a
substantial increase of GLP-1R expression when com-
pared with the nonmorbidly obese cohort. Interestingly,
FIG. 4. Effect of GLP-1 on lipolysis in human adipocytes and 3T3-L1 cells. A–C, Mouse
embryonic 3T3-L1 cells (n  6) were differentiated into adipocytes and then treated with 10
or 100 nM GLP-1 for 12 h (A) or with 100 nM GLP-1 for 4 h in the presence or absence of the
adenylate cyclase inhibitor MDL 12,330 A (106 M). Cells were harvested to determine
lipolysis (B). ***, P  0.01 vs. control. C, For cAMP measurements, 3T3-L1 cells were
incubated for 1 h with GLP-1 (100 nM) or exendin (9–39) (Exe; 10 nM), alone or in
combination, and in the presence of glucagon (Glucag; 10 nM) or GIP (10 nM) (n  4).
Thereafter cAMP production was measured. **, P  0.01 vs. control; **, P  0.001 vs.
control; #, P  0.05 vs. GLP-1 alone. D, Human preadipocytes were isolated from VAT
stromal-vascular fraction, differentiated into mature adipocytes, and then treated with
different concentrations of GLP-1 (10 nM, 100 nM, and 1 M) for 12 h. Glycerol release was
evaluated in mature adipocytes treated with GLP-1 and 3-isobutyl-1-methyxanthine. Bars with
different letters have a significant difference (P  0.05).
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functional classification of OB subjects according IR sta-
tus revealed thatGLP-1R inVATdepotswas dramatically
up-regulated in the setting of a very high degree of insulin
resistance. Morbidly obese patients are at the top of the
scale, representing the maximum expression of continu-
ous AT growth. This subset of patients carries the highest
morbidity risk because it is assumed that many cardiovas-
cular risk factors, including extreme IR, negatively influ-
ence their life expectancy (21).However,ATmass by itself
is not sufficient to link these patients with a poorer met-
abolic profile.
In view of the differences observed in GLP-1R expres-
sion in VAT depots from OB-IR patients, one is tempted
to speculate about the possible compensatorymechanisms
needed to overcome proportionally lower GLP-1 levels,
when extreme IR is present. In this line, several reports
have demonstrated that insulin resistance and diabetes
present a clear decrease in circulating GLP-1 after glucose
overload (22). The expression of GLP-1R in SAT depots
showednodifferences between patientswith high and low
degrees of IR. It is worthmentioning that visceral fat is the
main component linked to insulin resistance, and there are
many reports that describe the close association between
this fat depot and several components of the metabolic
syndrome. In fact, IRmaybe the consequenceof expanded
adipose visceral fat, and in turn, visceral fat may have a
different genetic profile, induced by an insulin resistant
state. We think that the GLP-1R expression differences
observed in VAT depots may generate in part a high IR
milieu, at least in the morbidly obese. The association ob-
servedbetweenGLP-1Rexpression inVATbefore surgery
and the HOMA index improvement after 6 months of
massive weight loss reinforce the determinant role of the
GLP-1R gene expression in the IR state.
It is worth noting that bariatric surgery improves insu-
lin sensitivity beyond the weight decline. At initial stages
after surgery, IR improves without a significant decline in
weight (23). This initial insulin sensitivity improvement
could be due to the changes in incretin secretion, especially
GLP-1. We believe that it is reasonable to propose that
those subjectswith increased adipose tissueGLP-1R levels
andwithadeficit of circulatingGLP-1are thosewhocould
improve their degree of insulin resistance after surgery.
Several studies have suggested that sustained treatment
with GLP-1R agonists is associated with improvements in
insulin sensitivity (24–26). Furthermore, it is well estab-
lished that GLP-1 enhancement improves insulin sensitiv-
ity in peripheral tissues (16), including muscle, liver, and
pancreas. However, the mechanisms by which the
GLP-1R in AT could participate in this improvement re-
main to be defined. We believe that the findings reported
herein support the relationship between this peptide and
insulin sensitivity.Moreover,GLP-1 is considered tobe an
important gastrointestinal peptide that plays anactive role
in lipolysis and fatty acid synthesis, and in 3T3-L1 adi-
pocytes it mediates increased insulin-dependent glucose
uptake by up-regulation of some insulin signaling mole-
cules, suchasphosphorylated insulin receptor substrate-1,
Akt, and glycogen synthase kinase 3b (12, 27). These data,
together with ours, could explain the important corre-
lation between insulin resistance and expression levels
of GLP-1R in VAT and also the relation of this receptor
with insulin sensitivity changes observed after bariatric
surgery.
On the other hand, it is known that GLP-1 modulates
the expression of the facilitative glucose transporters, glu-
cose transporter-1 and glucose transporter-4, in the
3T3-L1 cell line (28). Here GLP-1 treatment of fully dif-
ferentiated 3T3-L1 cells induced a dose-dependent lipo-
lytic effect in these cells. In this sense, it is well known that
GLP-1 may exert a dose dependent dual action, with pre-
dominant lipogenic activity when using picomolar con-
centrations or lipolytic activity when using nanomolar
doses (15). This is in agreement with the observed dose-
dependent lipolytic effect observed in bothmouse and hu-
man mature differentiated adipocytes. Moreover, our
data strongly support the view that GLP-1 stimulates li-
FIG. 5. Correlative analysis of GLP-1R mRNA expression in VAT with
HOMA index before and 6 months after surgery and with waist
circumference. HOMA index was evaluated in morbidly obese
subjects before (A) and 6 months after surgery (C). GLP-1R mRNA
expression in VAT correlation with waist circumference (B) and with
HOMA index improvement 6 months after surgery (D) were also
analyzed. The correlations were determined by Pearson’s correlation
coefficient test (r).
Endocrinology, November 2011, 152(11):0000–0000 endo.endojournals.org 7
polysis in adipocytes in a receptor-dependent manner in-
volving downstream adenylate cyclase/cAMP signaling.
This hormesis-like response may be behind the different
effects on weight loss observed in patients when treated
with GLP-1 analogs. The former are characterized by re-
establishing GLP-1 physiological levels, whereas analogs
of GLP-1 reach supraphysiological doses (as drugs) with
an anorexigenic and lipolytic effect leading to weight loss.
We are aware that this hypothesis may sound quite spec-
ulative, but it may prove attractive to understand these
differences better.
Finally, we believe that a better understanding of how
the GLP-1 receptor in VAT improves insulin sensitivity in
obese subjects would provide additional insight into the
pathogenesis of IR.
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